A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 75 Years of Age With Thyroid Eye Disease
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses
against placebo given by a subcutaneous injection every eight weeks to TED patients who are
in the active inflammatory phase of disease.